Q-omics provides the consensus-scored CCDC83 profile across patient tissues and cancer cell-line models. CCDC83 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC83 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, CCDC83 RNA expression shows 6,909 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KICH, and STAD as cancer lineages where CCDC83 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC83 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC83 survival associations across molecular data types. CCDC83 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC83 RNA expression–survival associations across cancer types. High CCDC83 expression shows unfavorable associations in ACC, KIRC, LGG, HNSC and DLBC, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC83 RNA expression.
This table summarizes CCDC83 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC83. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC83 shows lower tumor expression in KICH, KIRC and LUSC and higher tumor expression in BRCA, PRAD and UCEC. The KICH box plot shows higher CCDC83 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p < 0.001).
This table shows molecular features associated with CCDC83 in patient tissues and cancer cell lines. In patient samples, CCDC83 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC83 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
